U.S. markets open in 18 minutes

Jounce Therapeutics, Inc. (JNCE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.60+0.43 (+6.97%)
At close: 04:00PM EST
6.60 0.00 (0.00%)
After hours: 04:47PM EST

Jounce Therapeutics, Inc.

780 Memorial Drive
Cambridge, MA 02139
United States
857 259 3840

Full Time Employees128

Key Executives

NameTitlePayExercisedYear Born
Dr. Richard MurrayPres, CEO & Director884.86kN/A1959
Ms. Kimberlee Cobleigh Drapkin CPA, CPACFO & Treasurer582.39kN/A1968
Mr. Hugh M. ColeChief Bus. Officer & Head of Corp. Devel.641.33kN/A1965
Dr. James Patrick Allison Ph.D.FounderN/AN/AN/A
Dr. Thomas F. Gajewski M.D., Ph.D.FounderN/AN/AN/A
Dr. Robert D. Schreiber Ph.D.FounderN/AN/AN/A
Dr. Drew Mark Pardoll M.D., Ph.D.FounderN/AN/AN/A
Dr. Padmanee Sharma M.D., Ph.D.FounderN/AN/AN/A
Dr. Louis M. Weiner M.D.FounderN/AN/A1952
Dr. Stephen G. Farrand Ph.D.Chief Technical OfficerN/AN/A1957
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-4014, an anti-PD-1 antibody for combination therapy; JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Jounce Therapeutics, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 7. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.